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Purpose: This study aimed to develop a volumetric independent dose calculation (vIDC)
system for verification of the treatment plan in image-guided adaptive brachytherapy
(IGABT) and to evaluate the feasibility of the vIDC in clinical practice with simulated cases.
Methods: The vIDC is based on the formalism of TG-43. Four simulated cases of cervical
cancer were selected to retrospectively evaluate the dose distributions in IGABT. Some
reference point doses, such as points A and B and rectal points, were calculated by
vIDC using absolute coordinate. The 3D dose volume was also calculated to acquire
dose-volume histograms (DVHs) with grid resolutions of 1.0× 1.0 (G1.0), 2.5× 2.5 (G2.5),
and 0.5× 0.5 mm² (G0.5). Dosimetric parameters such as D90% and D2cc doses covering
90% of the high-risk critical target volume (HR-CTV) and 2 cc of the organs at risk (OARs)
were obtained from DVHs. D90% also converted to equivalent dose in 2-Gy fractions
(EQD2) to produce the same radiobiological effect as external beam radiotherapy. In
addition, D90% was obtained in two types with or without the applicator volume to confirm
the effect of the applicator itself. Validation of the vIDC was also performed using gamma
evaluation by comparison with Monte Carlo simulation.
Results: The average percentage difference of point doses was <2.28%. The DVHs
for the HR-CTV and OARs showed no significant differences between the vIDC and the
treatment planning system (TPS). Without considering the applicator volume, the D90%
of the HR-CTV calculated by the vIDC decreases with a decreasing calculated dose-grid
size (32.4, 5.65, and −2.20 cGy in G2.5, G1.0, and G0.5, respectively). The overall D90%
is higher when considering the applicator volume. The converted D90% by EQD2 ranged
from −1.29 to 1.00%. The D2cc of the OARs showed that the averaged dose deviation
is <10 cGy regardless of the dose-grid size. Based on gamma analysis, the passing rate
was 98.81% for 3%/3-mm criteria.
Kang et al. Independent Dose Calculation System for Brachytherapy
Conclusion: The vIDC was developed as an independent dose verification system for
verification of the treatment plan in IGABT. We confirmed that the vIDC is suitable for
second-check dose validation of the TPS under various conditions.
Keywords: independent dose calculation system, image-guided adaptive brachytherapy, American Association of
Physicists in Medicine Task Group 43, dose grid, equivalent dose in 2-Gy fractions
INTRODUCTION
Image-guided adaptive brachytherapy (IGABT) based on
magnetic resonance images (MRIs) has been introduced as a
new standard technique to improve the treatment outcome
in cervical cancer (1–6). IGABT delivers a high dose with a
small number of fractions after external beam radiotherapy
(EBRT). The treatment plan of IGABT is optimized by using
dosimetric parameters to meet dose constraints for the organs
at risk (OARs) and high-risk clinical target volume (HR-CTV).
The dose constraints are normalized to the equivalent dose in
2-Gy fractions (EQD2) to produce the same radiobiological
effect as in EBRT. Furthermore, IGABT based on MRIs is
more advantageous in the delineation of a region of interest
(ROI) such as the HR-CTV and OARs than is high-dose-rate
brachytherapy (BTHDR) based on computed tomography (CT)
images (7, 8). Because compensation of IGABT for treatment
outcomes is difficult, it is more important to generate the correct
treatment plan and to deliver accurate doses than with other
conventional treatments (9). Thus, at each fraction, IGABT
requires re-optimization of the treatment plan and re-defining of
the ROIs. Furthermore, the re-optimized treatment plan should
be validated for safe and accurate delivery (10).
In general, verification of treatment plan in brachytherapy
is performed by comparing the point doses calculated using
the treatment planning system (TPS) and an independent dose
calculation (IDC) system (11, 12). In the previous studies, various
IDC systems were reported (13–16). Formalism of the American
Association of Physicists inMedicine Task Group 43 (AAPMTG-
43) is usually used to calculate the point doses via templates or
were spreadsheet based in these systems. However, these point-
dose comparisons alone were not sufficient for the verification
of IGABT.
For better validation in IGABT, dosimetric parameters should
be calculated using an IDC system. Some commercialized IDC
systems, such as BrachyCheck (ROS, California, USA) and
DIAMOND for Brachytherapy (PTW, Freiburg, Germany), were
recently introduced. BrachyCheck can only calculate a dose-
volume histogram (DVH). In addition, DIAMOND calculates
point dose and 3D dose distributions, but in order to perform 3D
analysis, the dose file must be exported to other analysis software.
To solve inconveniences in these commercialized IDC systems,
Xianliang et al. reported dose verification software (DVS) that
can calculate the point dose and the dosimetric parameters (17).
The DVS also utilizes the gamma evaluation, but there are some
limitations. In the DVS, the calculation method for the direction
of the source is inaccurate in the ring applicator because they
defined the source vectors by connecting the existing source
dwell-position and next source dwell-position. Moreover, it can
use only fixed dose-grid size (1.0 × 1.0 mm2). Therefore, we
aimed to develop a volumetric IDC (vIDC) tool suitable for
IGABT verification. In the vIDC, the method of determining
the direction of the source will be improved, and various dose-
grid sizes will be available for selection. We will also add some
functions to the vIDC. Firstly, the dosimetric parameters of the
HR-CTV will allow the calculation of two types (HR-CTVW or
HR-CTVW/O) with or without applicator volume, and secondly,
the calculated 3D dose volumes will be able to be convert to EQD2
to account for the radiobiological effect caused by EBRT.
MATERIALS AND METHODS
Volumetric Independent Dose Calculation
System
In brachytherapy, it is important to accurately calculate the
source position and orientation to improve the accuracy of
dose calculations for tandem-and-ring applicators. The vIDC
can calculate the appropriate direction of sources in the ring
applicator, as shown in Figure 1. To calculate the source direction
for the ring applicator, the vIDC obtains various plane vectors of
the ring by using three sources’ positions. Then, the vIDC selects
an appropriate plane vector with analysis of the root mean square
error (RMSE) between each source’s position and the calculated
plane vector. The ring equation of the sphere is obtained using
the source positions and the selected plane vector (step 1). The
vector direction of each source is calculated by using the tangent
between the obtained ring equation and source position (step 2).
The dose calculation for the vIDC was based on the AAPM
TG-43U1 formalism. The formalism is classified as a point and
line source model, according to the method of source modeling.
The line source model was used in the vIDC, and the equation of
the model was as follows:
D (r, θ) = SK ·3 ·
GL (r, θ)
GL (r0, θ0)
· gL (r) · F (r, θ) (1)
where r is the distance from the center of an active source to
a point of interest and θ is the polar angle between the source
longitudinal axis and the line that connects the center of the
active source and the point of interest. The r0 and the θ0 denote
the reference distance (1 cm) and angle (90◦), respectively. The
air kerma strength (unit: cGy·cm2·h−1, 1 U = 1 cGy·cm2·h−1),
dose-rate constant (unit: cGy·h−1·U−1), geometry factor, radial-
dose function, and anisotropy function are represented as SK ,3,
G(r, θ), g(r), and F(r, θ), respectively. Each value of SK and 3
is defined in the TPS, while g(r) and F(r, θ) are provided by the
manufacturer of the source. The default grid size of the vIDC was
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FIGURE 1 | Coordinate system for determining the source direction.
1.0× 1.0 mm2 grid (G1.0). It is also possible to select various grid
sizes, such as 2.5× 2.5 (G2.5) and 0.5× 0.5 (G0.5) mm
2 grids.
The calculated dosimetric parameters are converted to EQD2
parameters for evaluating the radiobiological effect of the














A biologically effective dose (BED) is obtained for calculating
EQD2. The BED is used for isoeffective dose calculations, which
means that the true biological dose delivered is measured. Each
n and d is presented as the number of fractions and dose per
fraction, respectively. The α/β ratio means the ratio of “intrinsic
radiosensitivity” to “repair capability” of a specified tissue, and it
was presented in this paper as the tumor (α/β ratio = 10) and
OARs (α/β ratio= 3).
Treatment Planning of Image-Guided
Adaptive Brachytherapy Simulated Cases
In order to examine the efficiency of the functions and the
clinical feasibility for the vIDC, we retrospectively evaluated
with simulated cases treated using IGABT. Four simulated cases
with squamous cell carcinoma of the cervix were treated with
IGABT using an 192Ir HDR source and adapted a tandem-and-
ring technique. These cases were approved by the Institutional
Review Board (IRB). Treatment plans were generated with the
Oncentra Brachy (Elekta, Stockholm, Sweden) TPS, and the 3D
dose volume was calculated with a grid size of 1.0× 1.0 mm2.
As in EBRT, the dosimetric parameters are used as criteria of
the treatment plan (Table 1). The criteria are defined as the doses
TABLE 1 | The dose criteria used in the simulated IGABT cases.
Structure Criteria
HR-CTV D90% = 550 cGy
Bladder D2cc < 460 cGy
Rectum D2cc < 420 cGy
Sigmoid D2cc < 420 cGy
IGABT, image-guided adaptive brachytherapy; HR-CTV, high-risk critical target volume.
covering 90% of the HR-CTV and 2-cc volumes of each OAR
(D90% and D2cc, respectively). All plans were re-optimized with
appropriate dose criteria according to the variation in anatomy
and applicator location before treatment.
The point doses at points A and B and the rectum were also
calculated to verify the accuracy of dose calculation using the
vIDC by comparison with results calculated by the TPS. Point
A is defined as 2.0 cm superior to the lateral vaginal fornix and
2.0 cm lateral to the cervical canal. Point B indicates a position
2.0 cm superior to the ring surface and 5.0 cm lateral to the
midline. Point A represents dose limits that are delivered to the
uterine cervix, whereas point B is used to evaluate the lateral
spread of the effective doses, such as nearby doses in the pelvic
wall and obturator node. The rectal point dose represents a
delivered dose in the rectum. The reference point dose of the
TPS was compared with that of the vIDC by using the percentage
difference (%diff).
Monte Carlo Simulation for Validation of
Volumetric Independent Dose Calculation
System
Validation of vIDC was performed with Monte Carlo (MC)
simulations using GATE (Geant4 Application for Tomographic
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FIGURE 2 | All dose distributions calculated by Monte Carlo (MC), treatment planning system (TPS), and volumetric independent dose calculation (vIDC) system.
These dose distributions were analyzed with gamma evaluation using 3%/3-mm criteria.
Emission, Version 8.1). The grid size in MC was 1.0 × 1.0 mm2,
and the 192Ir source (HDR 192Ir mHDR-v2) has been modeled, as
described by Granero et al. (18). A virtual treatment plan that
included a tandem-and-ring technique was established within
the simulated water phantom. The plan was imported into the
TPS and the vIDC, and the respective calculation engine was
used to obtain the dose distribution in the axis plane of the ring
applicator’s center. With gamma evaluation, dose distributions
calculated by the TPS and the vIDC were compared with the
MC results.
RESULTS
Validation of Volumetric Independent Dose
Calculation by Comparing Dose
Distribution With Monte Carlo and
Treatment Planning System
Figure 2 shows all dose distributions calculated by MC, TPS, and
vIDC. These distributions were normalized with the maximum
dose. With gamma analysis, the passing rates of TPS and vIDC
were 98.25% and 98.81% for 3%/3-mm criteria, respectively,
through comparison with the calculated dose distribution byMC.
Comparison of Point Doses at the
Reference Points
Table 2 shows the percentage differences in the calculated point
doses between TPS and vIDC at the reference points to evaluate
the accuracy of the developed vIDC. All average percentage
differences of vIDC were<-2.28% at reference points of the same
absolute coordinates, compared with the clinical TPS.
TABLE 2 | The calculated point doses and percentage differences by using TPS
and vIDC for five reference points.
Reference points Point dose Percent difference
(TPS vs. vIDC)
TPS
(mean ± std, Gy)
vIDC
(mean ± std, Gy)
Right point A 4.69 ± 1.03 4.67 ± 1.03 −0.40
Left point A 4.71 ± 1.03 4.69 ± 1.02 −0.39
Right point B 1.19 ± 0.30 1.16 ± 0.30 −2.00
Left point B 1.05 ± 0.32 1.03 ± 0.32 −2.28
Rectum 1.99 ± 0.33 1.97 ± 0.32 −1.01
TPS, treatment planning system; vIDC, volumetric independent dose calculation.
Comparison of the Dose-Volume
Histogram and Dosimetric Parameters
The vIDC facilitated comprehensive 3D dose evaluations for
clinical use, even when the G1.0 was used. Figure 3 shows
averaged DVHs from the calculated 3D dose volumes by the
vIDC and TPS using the same dose-grid size of 1.0mm (G1.0). As
shown in Figure 3, no dose differences were observed for the HR-
CTVW/O, bladder, and sigmoid in the DVHs. However, a dose
difference with a high-dose range exceeding 1,000 cGy occurred
in HR-CTVW. In addition, a dose difference of <10 cGy was
observed at the same volume in the intermediate dose range for
the rectum.
Table 3 shows the dosimetric parameters between the vIDC
and TPS for the HR-CTV with or without the applicator
volume for various dose-grid sizes. The volumes of the HR-CTV
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FIGURE 3 | Averaged DVHs of HR-CTV (left) and OARs (right) from vIDC and TPS using 1.0-mm dose-grid size (G1.0). DVHs, dose-volume histograms; HR-CTV,
high-risk critical target volume; OARs, organs at risk; vIDC, volumetric independent dose calculation; TPS, treatment planning system.
TABLE 3 | The percentage difference of dose and volume for the HR-CTV between vIDC using three dose grid sizes with or without the applicator volume and TPS
using G1.0.














TPS G1.0 30.45 - 316.79 ± 39.05 - 525.90 ± 23.19
vIDC with the applicator volume G2.5 32.69 |7.26| 295.53 ± 38.73 −6.76 490.85 ± 20.64 −6.94
G1.0 29.31 |4.17| 304.00 ± 39.20 −4.09 517.50 ± 21.53 −1.83
G0.5 28.32 |7.56| 306.53 ± 39.96 −3.42 525.25 ± 21.97 −0.36
vIDC without the applicator volume G2.5 33.49 |10.23| 295.53 ± 38.73 −6.76 493.50 ± 23.19 −6.14
G1.0 30.02 |1.43| 304.00 ± 39.20 −4.09 520.25 ± 21.71 −1.06
G0.5 29.01 |4.91| 306.53 ± 39.96 −3.42 528.10 ± 22.28 −0.44
HR-CTV, high-risk critical target volume; vIDC, volumetric independent dose calculation; TPS, treatment planning system.
calculated by the vIDC were decreased by decreasing the dose-
grid size, as shown in Table 3. The target volume calculated with
G2.5 was larger in the vIDC than TPS. The minimum absolute
percentage difference for the target volume was 1.43% in HR-
CTVW/O calculated with G1.0. The percentage difference for
the dosimetric parameter also decreases by decreasing the dose-
grid size. For the G2.5, the differences of D100% and D90% were
more than−6%. The differences decreased to−3.42 and−0.44%
when G0.5 was used. The standard deviations for both evaluated
dosimetric parameters were within 40 cGy for D100% and 23 cGy
for D90%. Overall, the standard deviations were similar for the
vIDC and TPS regardless of grid sizes. In addition, the D100%
values of vIDC were the same in HR-CTVW and HR-CTVW/O.
However, all standard deviations of D90% used the same grid size
were higher in HR-CTVW/O than HR-CTVW. The differences of
D90% were also greater in HR-CTVW/O.
Table 4 indicates the dosimetric parameters and volumes
calculated with the TPS and vIDC for all OARs such as the
bladder, rectum, and sigmoid under the condition of various
dose-grid sizes. All OARs were acceptable for the D2cc dose
criterion shown in Table 1. For the calculated volumes for all
OARs, the smallest difference (<1.82%) compared with that in
vIDC and TPS was observed in the G1.0 used in TPS. The volume
differences for all OARs in the other grid were more than 4% for
G0.5 and 8% for G2.5. Compared with the dosimetric parameters
of TPS using G1.0, all evaluated parameters of vIDC for the
bladder and sigmoid have dose differences within ∼-3% for G0.5
and G1.0, but there was a difference of more than −4% for G2.5.
On the contrary, there was a dose difference for the rectum of
<-3% for G2.5 and more than−4% for G0.5 and G1.0.
Comparison of the Equivalent Dose in 2Gy
per Fraction
In order to evaluate the radiobiological effect, the EQD2 of
dosimetric parameters for the HR-CTV and OARs was analyzed
in each faction. Table 5 shows the EQD2 for the HR-CTV
and OARs in each fraction for one simulated case. For HR-
CTVW/O, EQD2 differences in D90% calculated using the vIDC
and TPS ranged from −1.00 to 1.29%. For each fraction, the
differences of EQD2 for dosimetric parameters were higher in
OARs than HR-CTVW/O. The maximum difference of EQD2
was −9.15% in the sigmoid and was observed in D0.1cc of the
first fraction.
DISCUSSION
The source direction determined by Xianliang et al. (17) was
obtained by connecting each source’s position. This method is
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TABLE 4 | The percentage differences of doses and volumes for the OARs between vIDC using three dose grid sizes and TPS using G1.0.
Grid size Dosimetric parameter OARs (percent difference compared with the TPS)
Bladder Rectum Sigmoid
(Mean ± std) (Mean ± std) (Mean ± std)
TPS G1.0 D10cc 222.15 ± 75.24 132.80 ± 67.19 252.25 ± 62.63
D2cc 324.25 ± 101.81 195.85 ± 85.42 367.40 ± 76.61
D0.1cc 448.45 ± 133.95 271.10 ± 117.63 543.30 ± 138.11
Mean volume of OARs (cm3) 57.75 45.28 168.69
vIDC G2.5 D10cc 232.25 ± 75.45 134.4 ± 66.67 259.50 ± 62.75
(4.34) (2.25) (3.08)
D2cc 343.85 ± 110.17 197.60 ± 86.65 381.90 ± 76.97
(5.65) (0.92) (4.14)
D0.1cc 487.80 ± 150.73 276.75 ± 120.89 564.30 ± 131.48
(8.18) (1.95) (4.43)
Mean volume of OARs (cm3) 62.25 49.26 180.49
|8.71| |10.41| |8.12|
G1.0 D10cc 222.40 ± 76.29 127.40 ± 64.59 248.20 ± 61.02
(−0.11) (−4.04) (−1.55)
D2cc 327.70 ± 104.35 188.15 ± 81.57 363.35 ± 73.75
(1.12) (−3.82) (−0.97)
D0.1cc 458.60 ± 139.53 260.35 ± 112.72 532.90 ± 125.73
(1.97) (−3.89) (−1.53)
Mean volume of OARs (cm3) 57.03 44.83 165.94
|1.43| |1.12| |1.82|
G0.5 D10cc 219.60 ± 75.45 125.15 ± 64.20 244.85 ± 60.48
(−1.36) (−6.20) (−2.90)
D2cc 322.85 ± 102.68 185.20 ± 80.04 358.05 ± 73.34
(−0.63) (−5.26) (−2.46)
D0.1cc 450.60 ± 136.32 255.50 ± 110.38 523.65 ± 124.75
(0.29) (−5.62) (−3.30)
Mean volume of OARs (cm3) 55.48 43.53 161.51
|4.42| |4.53| |4.81|
OARs, organs at risk; vIDC, volumetric independent dose calculation; TPS, treatment planning system.
not suitable for obtaining accurate source direction, especially
in using ring applicators. Therefore, we initially calculated
the sphere’s ring equation, and then we calculated the source
direction using the tangent of the sphere equation at each source
position. We showed the point doses in reference points and
the doses in dosimetric parameters calculated by Xianliang’s
method in Tables 6, 7. For five reference points, the point
doses using the vIDC were similar with those obtained with
by Xianliang’s method. In addition, the doses of dosimetric
parameters calculated by Xianliang’s method and the vIDC
using G1.0 show significant differences, as shown in Table 7.
Overall, the dose percentage differences of dosimetric parameters
are higher in Xianliang’s method than vIDC. In particular,
the percentage difference in D90% increased ∼3 times (1.83%
for the vIDC and to 5.55% for Xianliang’s method) compared
with the dose calculated with TPS. The percentage differences
also increased with the other dosimetric parameters for OARs.
However, the percentage difference compared with TPS was
found to be smaller in vIDC than Xianliang’s method. Thus, we
can conclude that the tangential method used in this study is
more accurate than Xianliang’s method. Maybe this method can
be applied to conventional brachytherapy.
Compared with the calculated point dose with TPS, the
calculated point doses with vIDC at the right and left point B
were the dose percentage difference of more than−1%. However,
these differences cannot be defined as the inaccuracy of dose
calculation by vIDC, because there was a small difference in the
calculated doses between the vIDC and TPS. The average dose
differences between vIDC and TPS for all reference points were
<0.03Gy. Therefore, it is indicated that the dose calculations
obtained with the vIDC are accurate on the basis of the
dose differences.
For the effect of grid size, the percentage difference in doses of
all dosimetric parameters for OARs was the smallest in G1.0 used
in TPS. On the other hand, D100% and D90% for the target volume
had the smallest percentage difference with G0.5 regardless of
whether applicator volume was used. The difference is probably
influenced by the dose gradient of the contoured ROI. As the
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TABLE 5 | Equivalent dose in 2-Gy fractions (EQD2) in dosimetric parameters for HR-CTV and OARs in each fraction.
Target Dosimetric
parameter
Equivalent dose in 2-Gy fractions (Gy) (percentage difference)
1st fraction 2nd fraction 3rd fraction 4th fraction 5th fraction Total
TPS HR-CTV D90% 6.76 6.86 6.83 6.60 6.62 33.67
Bladder D0.1cc 2.14 2.17 3.18 6.14 2.55 16.18
D2cc 1.29 1.34 2.23 4.04 1.73 10.63
Rectum D0.1cc 1.69 2.06 1.34 8.34 1.06 14.49
D2cc 1.17 1.35 1.00 4.39 0.74 8.65
Sigmoid D0.1cc 18.10 7.26 6.25 11.29 6.37 49.27
D2cc 9.60 4.53 4.35 6.46 3.44 28.39
vIDC without the applicator volume (G1.0) HR-CTV D90% 6.72 6.79 6.77 6.64 6.71 33.63
(−0.51) (−1.00) (−0.76) (0.52) (1.29) (−0.11)
Bladder D0.1cc 2.11 2.10 3.13 6.30 2.59 16.23
(−1.34) (−3.31) (−1.60) (2.63) (1.83) (0.35)
D2cc 1.26 1.29 2.20 4.10 1.73 10.57
(−2.73) (−3.55) (−1.31) (1.41) (0.00) (−0.52)
Rectum D0.1cc 1.62 1.99 1.29 7.82 1.00 13.72
(−3.84) (−3.42) (−3.55) (−6.26) (−6.14) (−5.32)
D2cc 1.13 1.29 0.97 4.12 0.70 8.21
(−3.86) (−4.41) (−3.22) (−6.18) (−5.23) (−5.17)
Sigmoid D0.1cc 16.44 6.80 6.00 10.65 5.84 45.74
(−9.15) (−6.40) (−4.03) (−5.62) (−8.27) (−7.17)
D2cc 8.99 4.27 4.18 6.21 3.25 26.90
(−6.40) (−5.65) (−4.02) (−3.96) (−5.57) (−5.26)
HR-CTV, high-risk critical target volume; OARs, organs at risk.
dose-grid size decreases, accurate dose verification is possible,
especially in regions with steep dose gradients. However, the dose
difference between G1.0 and G0.5 is relatively small (<10 cGy)
and can be neglected.Moreover, when the dose-grid size becomes
two times smaller, the time required for dose calculation increases
four times. Therefore, we recommend determining the dose-grid
size, taking into account the desired dose calculation accuracy
and existing time constraints.
In this study, we noted the dosimetric difference due to
the applicator volume. Potter et al. (19) reported that the
applicator volume does not affect the dosimetric parameters if
the target volume is sufficiently larger than the applicator volume.
However, the authors also mentioned that this dosimetric effect
of the applicator volume needs to be investigated because it
has not been clearly established. Thus, we demonstrated the
dosimetric effect with and without applicator volume using
the vIDC, and there was almost no the dosimetric effect,
as shown in Table 3. The dose differences were <4 cGy in
all D90. On the basis of our results, we confirmed that the
dosimetric effect does not need to be considered when the
volume of the HR-CTV is sufficiently large, such as cervical
cancer cases.
IGABT is known to improve treatment efficiency by delivering
additional dose to local lesion control after EBRT. The IGABT
is usually used at high doses (D90% of HR-CTV > 550 cGy)
in low fractions (<5 fractions) using the 192Ir source with an
average energy of 0.38 MeV. In contrast, the EBRT delivers
normally the total dose of 45Gy in 1.8Gy per fraction delivered
TABLE 6 | The calculated point doses and percentage differences by using TPS
and Xianliang’s method for five reference points.
Reference
points




(mean ± std, Gy)
Xianliang’s method
(mean ± std, Gy)
Right point A 4.69 ± 1.03 4.67 ± 1.03 −0.41
Left point A 4.71 ± 1.03 4.70 ± 1.02 −0.41
Right point B 1.19 ± 0.30 1.16 ± 0.30 −2.02
Left point B 1.05 ± 0.32 1.03 ± 0.32 −2.33
Rectum 1.99 ± 0.33 1.97 ± 0.32 0.87
TPS, treatment planning system.
using a high-energy photon beam (20, 21). Because of the
characteristic difference of these delivery doses, it is difficult
to accurately determine the same radiobiological effect between
IGABT and EBRT for treatment dose. Therefore, the prescribed
doses in each treatment were determined by conversion to
EQD2 to enable accurate optimization of the delivered doses.
In our study, radiobiological evaluation was performed by
calculating EQD2, and this evaluation will enable safer and more
accurate treatment.
Gamma evaluation analyzed with MC simulation results
was able to verify the vIDC. The gamma passing rate has
no difference, although slightly better in vIDC than TPS. The
point dose and dosimetric parameters of the vIDC indicated
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TABLE 7 | The dose and percentage differences in dosimetric parameters for HR-CTV and OARs by using Xianliang’s method and TPS.
Grid size HR-CTV
(mean ± std, cGy)
Bladder
(mean ± std, cGy)
Rectum
(mean ± std, cGy)
Sigmoid
(mean ± std, cGy)
(Percent difference) (Percent difference) (Percent difference) (Percent difference)
TPS G1.0 D100% 316.79 ± 39.05 D10cc 222.15 ± 75.24 132.80 ± 67.19 252.25 ± 62.63
D90 525.90 ± 23.19 D2cc 324.25 ± 101.81 195.85 ± 85.42 367.40 ± 76.61
D0.1cc 448.45 ± 133.95 271.10 ± 117.63 543.30 ± 138.11
Xianliang’s method G1.0 D100% 277.9 ± 72.50 D10cc 230.80 ± 78.75 125.2 ± 62.54 244.45 ± 59.65
(8.26) (3.71) (5.39) (2.93)
D90% 500.25 ± 23.72 D2cc 343.20 ± 109.33 183.85 ± 77.81 359.30 ± 73.18
(5.55) (5.54) (5.61) (1.98)
D0.1cc 488.05 ± 150.16 252.00 ± 105.00 524.80 ± 126.38
(8.37) (6.38) (2.80)
HR-CTV, high-risk critical target volume; OARs, organs at risk; TPS, treatment planning system.
similarities with the TPS. In view of these results, we confirmed
that the vIDC has almost the same performance as TPS. Thus,
our vIDC can be used to validate the treatment plan as a
second dose check that re-calculates the treatment plan and
detects errors in the TPS. In this study, however, the vIDC was
only evaluated in the tandem-and-ring cases. We will validate
this vIDC in other treatment cases for clinical application in a
future study.
CONCLUSION
The vIDC was developed for use as a second dose check to
verify the clinical IGABT treatment plans. This study revealed
that vIDC has the potential to verify the dose volumes calculated
by TPS. In addition, we have been found that the doses in the
dosimetric parameters are more affected by the dose grid size,
not the applicator volume. Finally, the vIDC can improve the
safety of IGABT by verifying the treatment plans with a variety
of conditions.
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